valcyte国内纳入医保了吗？

The tablet is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Ganciclovir is a synthetic analog of 2’-deoxyguanosine that inhibits herpes virus replication in vitro and in vivo. Susceptible human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV), and hepatitis B virus. In cells infected with cytomegalovirus (CMV), ganciclovir is first phosphorylated by the viral protein kinase UL97 to ganciclovir monophosphate. It is further phosphorylated by intracellular protein kinases into ganciclovir triphosphate, which is then slowly metabolized within the cell. After removal of extracellular ganciclovir, the half-life of ganciclovir in HSV- or HCMV-infected cells is 18 hours and 6 to 24 hours, respectively. Since phosphorylation is largely dependent on viral protein kinases, ganciclovir phosphorylation occurs preferentially in virus-infected cells.

The safety and efficacy of valcyte (valganciclovir hydrochloride tablets) treatment were verified in two different trials: The antiviral effect of valcyte tablets was clinically confirmed by the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with valcyte tablets, and the U.S. Food and Drug Administration (FDA) approved the increased use of valcyte in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylaxis with valcyte reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) at one year after receiving a kidney transplant (p < 0.0001). 1.2 The overall safety profile of valamciclovir hydrochloride did not change when prophylaxis was extended in high-risk kidney transplant patients.

The editor has introduced you to the therapeutic effects of valcyte (valganciclovir hydrochloride tablets), then let’s take a look at the medical insurance issues of valcyte (valganciclovir hydrochloride tablets). According to the editor, valcyte has not yet entered domestic medical insurance, and the price of the original drug in pharmacies is relatively expensive. Fortunately, there is also Roche's (valganciclovir hydrochloride tablets, valgansiklovir). The specification is 450mg*60 tablets, and the price in Indian pharmacies is about RMB 5,500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.